CA2512536A1 - Biomarqueurs et methodes de determination d'une sensibilite aux modulateurs du facteur de croissance epidermique - Google Patents

Biomarqueurs et methodes de determination d'une sensibilite aux modulateurs du facteur de croissance epidermique Download PDF

Info

Publication number
CA2512536A1
CA2512536A1 CA002512536A CA2512536A CA2512536A1 CA 2512536 A1 CA2512536 A1 CA 2512536A1 CA 002512536 A CA002512536 A CA 002512536A CA 2512536 A CA2512536 A CA 2512536A CA 2512536 A1 CA2512536 A1 CA 2512536A1
Authority
CA
Canada
Prior art keywords
xref
mrna
fea
est
egfr
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Abandoned
Application number
CA002512536A
Other languages
English (en)
Inventor
Lukas C. Amler
Thomas Januario
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Bristol Myers Squibb Co
Original Assignee
Individual
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Individual filed Critical Individual
Publication of CA2512536A1 publication Critical patent/CA2512536A1/fr
Abandoned legal-status Critical Current

Links

Classifications

    • GPHYSICS
    • G01MEASURING; TESTING
    • G01NINVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/53Immunoassay; Biospecific binding assay; Materials therefor
    • G01N33/574Immunoassay; Biospecific binding assay; Materials therefor for cancer
    • CCHEMISTRY; METALLURGY
    • C12BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12QMEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
    • C12Q1/00Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions
    • C12Q1/68Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions involving nucleic acids
    • C12Q1/6876Nucleic acid products used in the analysis of nucleic acids, e.g. primers or probes
    • C12Q1/6883Nucleic acid products used in the analysis of nucleic acids, e.g. primers or probes for diseases caused by alterations of genetic material
    • C12Q1/6886Nucleic acid products used in the analysis of nucleic acids, e.g. primers or probes for diseases caused by alterations of genetic material for cancer
    • GPHYSICS
    • G01MEASURING; TESTING
    • G01NINVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/74Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving hormones or other non-cytokine intercellular protein regulatory factors such as growth factors, including receptors to hormones and growth factors
    • CCHEMISTRY; METALLURGY
    • C12BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12QMEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
    • C12Q2600/00Oligonucleotides characterized by their use
    • C12Q2600/106Pharmacogenomics, i.e. genetic variability in individual responses to drugs and drug metabolism
    • GPHYSICS
    • G01MEASURING; TESTING
    • G01NINVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N2500/00Screening for compounds of potential therapeutic value
    • G01N2500/04Screening involving studying the effect of compounds C directly on molecule A (e.g. C are potential ligands for a receptor A, or potential substrates for an enzyme A)
    • GPHYSICS
    • G01MEASURING; TESTING
    • G01NINVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N2800/00Detection or diagnosis of diseases
    • G01N2800/52Predicting or monitoring the response to treatment, e.g. for selection of therapy based on assay results in personalised medicine; Prognosis

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Immunology (AREA)
  • Molecular Biology (AREA)
  • Biomedical Technology (AREA)
  • Pathology (AREA)
  • Analytical Chemistry (AREA)
  • Urology & Nephrology (AREA)
  • Hematology (AREA)
  • Biochemistry (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Biotechnology (AREA)
  • Microbiology (AREA)
  • Physics & Mathematics (AREA)
  • Organic Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Oncology (AREA)
  • Hospice & Palliative Care (AREA)
  • General Physics & Mathematics (AREA)
  • Medicinal Chemistry (AREA)
  • Zoology (AREA)
  • Food Science & Technology (AREA)
  • Genetics & Genomics (AREA)
  • Cell Biology (AREA)
  • Wood Science & Technology (AREA)
  • Biophysics (AREA)
  • Endocrinology (AREA)
  • General Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Measuring Or Testing Involving Enzymes Or Micro-Organisms (AREA)
  • Investigating Or Analysing Biological Materials (AREA)
CA002512536A 2003-01-08 2004-01-08 Biomarqueurs et methodes de determination d'une sensibilite aux modulateurs du facteur de croissance epidermique Abandoned CA2512536A1 (fr)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US43873503P 2003-01-08 2003-01-08
US60/438,735 2003-01-08
PCT/US2004/000368 WO2004063709A2 (fr) 2003-01-08 2004-01-08 Biomarqueurs et methodes de determination d'une sensibilite aux modulateurs du facteur de croissance epidermique

Publications (1)

Publication Number Publication Date
CA2512536A1 true CA2512536A1 (fr) 2004-07-29

Family

ID=32713370

Family Applications (1)

Application Number Title Priority Date Filing Date
CA002512536A Abandoned CA2512536A1 (fr) 2003-01-08 2004-01-08 Biomarqueurs et methodes de determination d'une sensibilite aux modulateurs du facteur de croissance epidermique

Country Status (4)

Country Link
EP (1) EP1597558A2 (fr)
JP (1) JP2007520995A (fr)
CA (1) CA2512536A1 (fr)
WO (1) WO2004063709A2 (fr)

Families Citing this family (99)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
PT1725249E (pt) 2003-11-06 2014-04-10 Seattle Genetics Inc Compostos de monometilvalina capazes de conjugação a ligandos
WO2005070020A2 (fr) 2004-01-23 2005-08-04 The Regents Of The University Of Colorado Expression genique relative a la sensibilite au gefitinib, produits et procedes associes
JP5422120B2 (ja) 2004-05-27 2014-02-19 ザ リージェンツ オブ ザ ユニバーシティ オブ コロラド,ア ボディー コーポレイト 癌患者による上皮成長因子受容体阻害薬に対する臨床転帰の予測方法
CN114053429A (zh) 2004-06-01 2022-02-18 健泰科生物技术公司 抗体-药物偶联物和方法
US20100111856A1 (en) 2004-09-23 2010-05-06 Herman Gill Zirconium-radiolabeled, cysteine engineered antibody conjugates
DK1791565T3 (en) 2004-09-23 2016-08-01 Genentech Inc Cysteingensplejsede antibodies and conjugates
KR20130089280A (ko) 2005-01-21 2013-08-09 제넨테크, 인크. Her 항체의 고정 용량 투여법
RU2404806C2 (ru) 2005-02-23 2010-11-27 Дженентек, Инк. Продление времени до прогрессирования заболевания или продолжительности жизни у онкологических больных с применением ингибиторов димеризации her
US8093011B2 (en) 2005-03-16 2012-01-10 Haley John D Biological markers predictive of anti-cancer response to epidermal growth factor receptor kinase inhibitors
US8383357B2 (en) 2005-03-16 2013-02-26 OSI Pharmaceuticals, LLC Biological markers predictive of anti-cancer response to epidermal growth factor receptor kinase inhibitors
AR053272A1 (es) * 2005-05-11 2007-04-25 Hoffmann La Roche Determinacion de responsivos a la quimioterapia
CA2620195A1 (fr) 2005-08-24 2007-03-01 Bristol-Myers Squibb Company Marqueurs biologiques et procedes permettant de determiner la receptivite aux modulateurs du recepteur du facteur de croissance epidermique (egfr)
DK1926996T3 (da) 2005-09-20 2012-01-23 Osi Pharmaceuticals Llc Biologiske markører, som er prædiktive for anti-cancer-reaktion på insulinlignende vækstfaktor-1-receptorkinasehæmmere
DK2132573T3 (da) 2007-03-02 2014-07-14 Genentech Inc Forudsigelse af respons på en her-dimeriseringsinhibitor på basis af lav her3-ekspression
JP5240739B2 (ja) 2007-04-13 2013-07-17 オーエスアイ・フアーマシユーテイカルズ・エル・エル・シー キナーゼ阻害剤に対する抗癌応答を予測する生物学的マーカー
US9551033B2 (en) 2007-06-08 2017-01-24 Genentech, Inc. Gene expression markers of tumor resistance to HER2 inhibitor treatment
DK2171090T3 (da) 2007-06-08 2013-06-10 Genentech Inc Genekspressionsmarkører for tumorresistens over for HER2-inhibitorbehandling
WO2009002175A1 (fr) * 2007-06-28 2008-12-31 Agendia B.V. Procédé de typage d'un échantillon comprenant des cellules cancéreuses du cancer colorectal
US7939272B2 (en) 2007-10-03 2011-05-10 Osi Pharmaceuticals, Inc. Biological markers predictive of anti-cancer response to insulin-like growth factor-1 receptor kinase inhibitors
EP2208066A2 (fr) 2007-10-03 2010-07-21 OSI Pharmaceuticals, Inc. Marqueurs biologiques de prédiction de la réponse anti-cancéreuse aux inhibiteurs de la kinase du récepteur 1 du facteur de croissance insulinomimétique de type 1 (igf-1r)
BRPI0812682A2 (pt) 2008-06-16 2010-06-22 Genentech Inc tratamento de cáncer de mama metastático
JP5705836B2 (ja) 2009-05-29 2015-04-22 エフ・ホフマン−ラ・ロシュ・アクチェンゲゼルシャフト Her2を発現する胃癌患者のher2シグナル伝達のためのモジュレーター
WO2011000054A1 (fr) 2009-07-03 2011-01-06 Avipep Pty Ltd Immunoconjugués et leurs procédés de production
US8470980B2 (en) 2009-09-09 2013-06-25 Centrose, Llc Extracellular targeted drug conjugates
WO2011075786A1 (fr) 2009-12-23 2011-06-30 Avipep Pty Ltd Immuno-conjugués et leurs méthodes de production
AU2011223643A1 (en) 2010-03-03 2012-06-28 OSI Pharmaceuticals, LLC Biological markers predictive of anti-cancer response to insulin-like growth factor-1 receptor kinase inhibitors
WO2011109584A2 (fr) 2010-03-03 2011-09-09 OSI Pharmaceuticals, LLC Marqueurs biologiques prédictifs d'une réponse anticancéreuse aux inhibiteurs de kinase du récepteur du facteur de croissance insulinique 1
SI2528625T1 (sl) 2010-04-15 2013-11-29 Spirogen Sarl Pirolobenzodiazepini in njihovi konjugati
WO2011146568A1 (fr) 2010-05-19 2011-11-24 Genentech, Inc. Prédiction de réponses à un inhibiteur de her
EP2579897A1 (fr) 2010-06-08 2013-04-17 Genentech, Inc. Anticorps et conjugués modifiés par la cystéine
WO2012074757A1 (fr) 2010-11-17 2012-06-07 Genentech, Inc. Conjugués d'anticorps alaninyl-maytansinol
US20120214830A1 (en) 2011-02-22 2012-08-23 OSI Pharmaceuticals, LLC Biological markers predictive of anti-cancer response to insulin-like growth factor-1 receptor kinase inhibitors in hepatocellular carcinoma
CN103619877B (zh) 2011-04-21 2018-01-02 加文医学研究所 修饰的可变结构域分子及其产生和使用方法b
WO2012149014A1 (fr) 2011-04-25 2012-11-01 OSI Pharmaceuticals, LLC Utilisation de signatures de gènes de tem dans la découverte de médicaments contre le cancer, diagnostics et traitement du cancer
WO2012155019A1 (fr) 2011-05-12 2012-11-15 Genentech, Inc. Procédé lc-ms/ms de surveillance de réactions multiples pour détecter des anticorps thérapeutiques dans des échantillons animaux à l'aide de peptides de signature d'infrastructure
SG2014011316A (en) 2011-08-31 2014-06-27 Genentech Inc Diagnostic markers
RU2014110228A (ru) 2011-09-30 2015-11-10 Дженентек, Инк. Диагностические маркеры
AU2012322607B2 (en) 2011-10-14 2017-02-16 Genentech, Inc. Pyrrolobenzodiazepines and conjugates thereof
US9376715B2 (en) 2011-12-09 2016-06-28 Roche Molecular Systems, Inc Methods for detecting mutations in the catalytic subunit of the phosphoinositol-3 kinase (PIK3CA) gene
WO2013130093A1 (fr) 2012-03-02 2013-09-06 Genentech, Inc. Biomarqueurs pour un traitement à base de composés chimiothérapeutiques anti-tubuline
ES2649990T3 (es) 2012-10-12 2018-01-16 Medimmune Limited Conjugados de anticuerpos anti-CD22-pirrolobenzodiazepinas
EP2906250B1 (fr) 2012-10-12 2018-05-30 ADC Therapeutics SA Conjugués pyrrolobenzodiazepine-anticorps anti-psma
HUE039329T2 (hu) 2012-10-12 2018-12-28 Adc Therapeutics Sa Pirrolobenzodiazepin-antitest konjugátumok
ES2660029T3 (es) 2012-10-12 2018-03-20 Medimmune Limited Conjugados de anticuerpo-pirrolobenzodiazepinas
PT2906298T (pt) 2012-10-12 2018-12-28 Medimmune Ltd Conjugados de pirrolobenzodiazepina-anticorpos
HUE045435T2 (hu) 2012-10-12 2019-12-30 Medimmune Ltd Pirrolobenzodiazepinek és konjugátumaik
WO2014057113A1 (fr) 2012-10-12 2014-04-17 Adc Therapeutics Sarl Conjugués anticorps anti-psma - pyrrolobenzodiazépine
EP3511718A1 (fr) 2012-11-30 2019-07-17 F. Hoffmann-La Roche AG Inhibiteur de pd-l1
EA031585B1 (ru) 2012-12-21 2019-01-31 Медимьюн Лимитед Пирролобензодиазепины и их конъюгаты
CA2894959C (fr) 2012-12-21 2022-01-11 Spirogen Sarl Dimeres de pyrrolobenzodiazepines asymetriques a utiliser dans le traitement de maladies proliferatives et auto-immunes
CA2904044C (fr) 2013-03-13 2020-03-31 Medimmune Limited Pyrrolobenzodiazepines et leurs conjugues
MX363787B (es) 2013-03-13 2019-04-03 Medimmune Ltd Pirrolobenzodiazepinas y conjugados de los mismos.
US20160031887A1 (en) 2013-03-13 2016-02-04 Medimmune Limited Pyrrolobenzodiazepines and conjugates thereof
CN105636612B (zh) 2013-08-12 2020-01-14 基因泰克公司 抗体-药物缀合物及使用和治疗方法
GB201317982D0 (en) 2013-10-11 2013-11-27 Spirogen Sarl Pyrrolobenzodiazepines and conjugates thereof
EP3054985B1 (fr) 2013-10-11 2018-12-26 Medimmune Limited Conjugués anticorps-pyrrolobenzodiazépine
EP3054986B1 (fr) 2013-10-11 2019-03-20 Medimmune Limited Conjugués anticorps-pyrrolobenzodiazépine
EP3054983B1 (fr) 2013-10-11 2019-03-20 Medimmune Limited Conjugués anticorps-pyrrolobenzodiazépines
WO2015095223A2 (fr) 2013-12-16 2015-06-25 Genentech, Inc. Composés peptidomimétiques et conjugués anticorps-médicament de ceux-ci
MX2016007578A (es) 2013-12-16 2016-10-03 Genentech Inc Compuestos de conjugado anticuerpo-farmaco dimerico de 1-(clorometil)-2,3-dihidro-1h-benzo [e] indol, y metodos de uso y tratamiento.
CR20160271A (es) 2013-12-16 2016-12-02 Genentech Inc Compuestos peptidométicos y sus conjugados de anticuerpo-fármaco
US10188746B2 (en) 2014-09-10 2019-01-29 Medimmune Limited Pyrrolobenzodiazepines and conjugates thereof
RU2017107502A (ru) 2014-09-12 2018-10-12 Дженентек, Инк. Антитела и конъюгаты, сконструированные введением цистеина
GB201416112D0 (en) 2014-09-12 2014-10-29 Medimmune Ltd Pyrrolobenzodiazepines and conjugates thereof
JP6622293B2 (ja) 2014-09-12 2019-12-18 ジェネンテック, インコーポレイテッド アントラサイクリンジスルフィド中間体、抗体−薬物複合体、及び方法
JP2017533887A (ja) 2014-09-17 2017-11-16 ジェネンテック, インコーポレイテッド ピロロベンゾジアゼピン類及びその抗体ジスルフィドコンジュゲート
BR112017011111A2 (pt) 2014-11-25 2017-12-26 Adc Therapeutics Sa conjugados de pirrolobenzodiazepina-anticorpo
MX2017007169A (es) 2014-12-03 2018-05-02 Genentech Inc Compuestos de amina cuaternaria y conjugados de anticuerpofármaco de los mismos.
GB201506402D0 (en) 2015-04-15 2015-05-27 Berkel Patricius H C Van And Howard Philip W Site-specific antibody-drug conjugates
GB201506411D0 (en) 2015-04-15 2015-05-27 Bergenbio As Humanized anti-axl antibodies
MA43345A (fr) 2015-10-02 2018-08-08 Hoffmann La Roche Conjugués anticorps-médicaments de pyrrolobenzodiazépine et méthodes d'utilisation
MA43354A (fr) 2015-10-16 2018-08-22 Genentech Inc Conjugués médicamenteux à pont disulfure encombré
MA45326A (fr) 2015-10-20 2018-08-29 Genentech Inc Conjugués calichéamicine-anticorps-médicament et procédés d'utilisation
GB201601431D0 (en) 2016-01-26 2016-03-09 Medimmune Ltd Pyrrolobenzodiazepines
GB201602359D0 (en) 2016-02-10 2016-03-23 Medimmune Ltd Pyrrolobenzodiazepine Conjugates
GB201602356D0 (en) 2016-02-10 2016-03-23 Medimmune Ltd Pyrrolobenzodiazepine Conjugates
WO2017165734A1 (fr) 2016-03-25 2017-09-28 Genentech, Inc. Dosage multiplexé pour la quantification d'anticorps totaux et de médicaments conjugués à des anticorps
GB201607478D0 (en) 2016-04-29 2016-06-15 Medimmune Ltd Pyrrolobenzodiazepine Conjugates
ES2858151T3 (es) 2016-05-20 2021-09-29 Hoffmann La Roche Conjugados de PROTAC-anticuerpo y procedimientos de uso
US20170370906A1 (en) 2016-05-27 2017-12-28 Genentech, Inc. Bioanalytical analysis of site-specific antibody drug conjugates
WO2017214024A1 (fr) 2016-06-06 2017-12-14 Genentech, Inc. Médicaments conjugués d'anticorps silvestrol et procédés d'utilisation
EP3496763A1 (fr) 2016-08-11 2019-06-19 Genentech, Inc. Promédicaments de pyrrolobenzodiazépine et conjugués d'anticorps de ceux-ci
WO2018065501A1 (fr) 2016-10-05 2018-04-12 F. Hoffmann-La Roche Ag Procédés de préparation de conjugués anticorps-médicament
GB201617466D0 (en) 2016-10-14 2016-11-30 Medimmune Ltd Pyrrolobenzodiazepine conjugates
GB201702031D0 (en) 2017-02-08 2017-03-22 Medlmmune Ltd Pyrrolobenzodiazepine-antibody conjugates
KR102181375B1 (ko) 2017-02-08 2020-11-25 에이디씨 테라퓨틱스 에스에이 피롤로벤조디아제핀-항체 컨주게이트
BR112019021942A2 (pt) 2017-04-18 2020-05-05 Medimmune Ltd conjugados de pirrolobenzodiazepina
US20200129637A1 (en) 2017-04-20 2020-04-30 Adc Therapeutics Sa Combination therapy with an anti-axl antibody-drug conjugate
JP7145891B2 (ja) 2017-06-14 2022-10-03 アーデーセー セラピューティクス ソシエテ アノニム 抗cd19 adcを投与するための投与レジメ
CA3070765A1 (fr) 2017-08-18 2019-02-21 Medimmune Limited Conjugues de pyrrolobenzodiazepine pour le traitement d'une maladie proliferante
IL273387B2 (en) 2017-09-20 2023-10-01 Ph Pharma Co Ltd Thylanstatin analogs
GB201803342D0 (en) 2018-03-01 2018-04-18 Medimmune Ltd Methods
GB201806022D0 (en) 2018-04-12 2018-05-30 Medimmune Ltd Pyrrolobenzodiazepines and conjugates thereof
GB201814281D0 (en) 2018-09-03 2018-10-17 Femtogenix Ltd Cytotoxic agents
WO2020086858A1 (fr) 2018-10-24 2020-04-30 Genentech, Inc. Inducteurs chimiques conjugués de dégradation et méthodes d'utilisation
JP2022513198A (ja) 2018-12-10 2022-02-07 ジェネンテック, インコーポレイテッド Fc含有タンパク質への部位特異的コンジュゲーションのための光架橋性ペプチド
GB201901197D0 (en) 2019-01-29 2019-03-20 Femtogenix Ltd G-A Crosslinking cytotoxic agents
GB2597532A (en) 2020-07-28 2022-02-02 Femtogenix Ltd Cytotoxic compounds
WO2024138128A2 (fr) 2022-12-23 2024-06-27 Genentech, Inc. Conjugués d'agent de dégradation de céréblon et leurs utilisations

Family Cites Families (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US20020102532A1 (en) * 2000-10-03 2002-08-01 Meena Augustus Cancer gene determination and therapeutic screening using signature gene sets

Also Published As

Publication number Publication date
WO2004063709A2 (fr) 2004-07-29
JP2007520995A (ja) 2007-08-02
EP1597558A2 (fr) 2005-11-23
WO2004063709A8 (fr) 2005-03-31
WO2004063709A3 (fr) 2008-05-15

Similar Documents

Publication Publication Date Title
CA2512536A1 (fr) Biomarqueurs et methodes de determination d'une sensibilite aux modulateurs du facteur de croissance epidermique
US20030087266A1 (en) IGs as modifiers of the p53 pathway and methods of use
CA2448250A1 (fr) Genes limk en tant que modificateurs de la voie p53 et procedes d'utilisation associes
TW201632629A (zh) 用於癌症診斷與預後的方法
KR20170092671A (ko) 전립선암의 진단 및 치료에서 필라민을 포함하는 마커의 용도
CA2514187A1 (fr) Profils d'expression destines au cancer du colon et procedes d'utilisation
CN101687050A (zh) 用于鉴别原发起源不明的癌的起源的方法和材料
ES2524643T3 (es) Genes control para la normalización de datos de análisis de expresión génica
KR102613599B1 (ko) 뇌경색 발증 리스크 예측 방법
KR20150023904A (ko) 전립선암의 진단 및 치료에서의 마커의 용도
CN107109488A (zh) 预测对乳腺癌治疗剂的反应的方法和治疗乳腺癌的方法
CN102459645B (zh) 作为前列腺癌标记的磷酸二酯酶9a
WO2015114146A1 (fr) Procédé permettant de prédire la réponse à une thérapie et/ou une chimiothérapie à base d'anti-her2 chez des patientes atteintes d'un cancer du sein
KR20220112290A (ko) 안지오포이에틴 유사 4(angptl4) 관련 질환의 치료를 위한 올리고뉴클레오타이드
CN113767179A (zh) 脑梗塞发病风险预测方法
US6723508B2 (en) Method for determining the presence of at least one allele of a GSTT1 deletion mutant
KR20040101992A (ko) 간 질환에서의 유전자 발현 프로파일
KR100901147B1 (ko) 자궁암 환자의 방사선 치료 후 재발 예측용 마커, 그를포함하는 키트 및 마이크로어레이, 및 상기 마커를 이용한자궁암 환자 재발 여부 예측 방법
CN107075580B (zh) 癌症检测套组
KR20130087585A (ko) 저도 염증을 검출하는 방법
KR101818352B1 (ko) 방광암의 진단 및 예후 예측용 바이오 마커 및 그의 용도
WO2006022638A1 (fr) Méthodes d’identification du risque d’apparition de diabètes de type ii et traitements associés
KR102326582B1 (ko) 청각장애의 진단용 마커 및 그의 용도
KR20050008644A (ko) 위암에서의 유전자 발현 프로파일
KR102274721B1 (ko) 난소암 진단을 위한 돌연변이 유전자 및 이를 이용한 진단 방법

Legal Events

Date Code Title Description
FZDE Discontinued